SLC5A2 and metabolic disease: While DAPA acting on SGLT2 may be involved in the body’s glucose and lipid metabolism processes, it cannot be denied that DAPA’s improvement in obesity and metabolic disorders partly stems from the “browning” of WAT, consistent with reports on other SGLT2 inhibitors [34, 35].